Juno Therapeutics Inc (NASDAQ:JUNO) saw some unusual options trading on Thursday. Traders bought 18,161 call options on the company. This represents an increase of approximately 1,208% compared to the average volume of 1,388 call options.
JUNO has been the subject of several research reports. SunTrust Banks raised Juno Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, November 2nd. Cowen reissued a “buy” rating and issued a $49.00 target price on shares of Juno Therapeutics in a report on Friday, October 27th. Raymond James Financial boosted their target price on Juno Therapeutics from $45.00 to $61.00 and gave the company an “outperform” rating in a report on Friday, November 3rd. Wedbush reaffirmed an “outperform” rating and set a $64.00 price objective (up from $42.00) on shares of Juno Therapeutics in a research note on Thursday, November 2nd. Finally, Zacks Investment Research downgraded Juno Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, January 17th. Two equities research analysts have rated the stock with a sell rating, sixteen have issued a hold rating and three have given a buy rating to the company’s stock. Juno Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $51.20.
In related news, EVP Robert Azelby sold 1,816 shares of the business’s stock in a transaction on Monday, December 18th. The stock was sold at an average price of $44.96, for a total transaction of $81,647.36. Following the completion of the transaction, the executive vice president now directly owns 70,832 shares of the company’s stock, valued at approximately $3,184,606.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Hans Edgar Bishop sold 270,250 shares of the company’s stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $46.17, for a total value of $12,477,442.50. Following the transaction, the chief executive officer now directly owns 2,772,679 shares of the company’s stock, valued at $128,014,589.43. The disclosure for this sale can be found here. Insiders sold 468,874 shares of company stock valued at $26,675,574 over the last ninety days. Insiders own 15.08% of the company’s stock.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. ARK Investment Management LLC grew its holdings in Juno Therapeutics by 31.0% during the 4th quarter. ARK Investment Management LLC now owns 682,495 shares of the biopharmaceutical company’s stock valued at $31,197,000 after buying an additional 161,380 shares during the last quarter. Spark Investment Management LLC purchased a new position in shares of Juno Therapeutics during the 4th quarter worth $799,000. Clarius Group LLC lifted its stake in shares of Juno Therapeutics by 2.6% during the 4th quarter. Clarius Group LLC now owns 120,988 shares of the biopharmaceutical company’s stock worth $5,530,000 after purchasing an additional 3,092 shares during the period. Virtus Fund Advisers LLC purchased a new position in shares of Juno Therapeutics during the 4th quarter worth $359,000. Finally, UBS Asset Management Americas Inc. lifted its stake in shares of Juno Therapeutics by 1.7% during the 4th quarter. UBS Asset Management Americas Inc. now owns 58,690 shares of the biopharmaceutical company’s stock worth $2,683,000 after purchasing an additional 963 shares during the period. Institutional investors and hedge funds own 68.90% of the company’s stock.
Shares of Juno Therapeutics (NASDAQ JUNO) traded up $0.15 during mid-day trading on Monday, hitting $85.84. The stock had a trading volume of 2,971,635 shares, compared to its average volume of 6,280,425. The stock has a market cap of $9,810.00, a P/E ratio of -25.32 and a beta of 3.42. The company has a current ratio of 4.77, a quick ratio of 4.77 and a debt-to-equity ratio of 0.01. Juno Therapeutics has a fifty-two week low of $19.62 and a fifty-two week high of $86.28.
WARNING: This piece was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece on another publication, it was stolen and republished in violation of US and international copyright law. The correct version of this piece can be read at https://www.dispatchtribunal.com/2018/02/12/juno-therapeutics-target-of-unusually-high-options-trading-juno.html.
Juno Therapeutics Company Profile
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
Receive News & Ratings for Juno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.